First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
Thesis: Synopsys: the setup is constructive — Semiconductor industry capital intensity and R&D spending trends - particularly at leading-edge foundries (TSMC, Samsung…
★ Analysts see FY2026 revenue reaching $9.7B — +37.4% growth in a single year.
Why Revenue Could Explode
1Semiconductor industry capital intensity and R&D spending trends - particularly at leading-edge foundries (TSMC, Samsung, Intel) and fabless designers (NVIDIA, AMD, Qualcomm)
2Design start activity and tape-out volumes at advanced nodes (5nm and below), which drive incremental tool adoption and IP licensing
3Total contract value (TCV) bookings and backlog growth, which signal future revenue given the multi-year license recognition model
4Competitive win rates in key tool categories (digital implementation, verification, custom design) and IP market share gains
5M&A activity and integration execution - company has grown through strategic acquisitions (Ansys acquisition pending regulatory approval as of early 2026)
growth - Investors are attracted to Synopsys for its exposure to secular semiconductor growth trends (AI, automotive electrification, IoT)…
Rising rates create modest headwinds through two channels: (1) Higher discount rates compress valuation multiples for high-growth software…
Watch on earnings: Global semiconductor industry R&D spending as percentage of revenue (proxy for EDA budget growth), TSMC and Samsung advanced node (5nm/3nm/2nm) wafer start volumes and capacity utilization rates, Semiconductor design start activity and tape-out counts reported by foundries.
One Sentence Summary:
The bull case is simple: analysts see revenue climbing from $9.7B to $10.7B as semiconductor industry capital intensity and r&d spending trends - particularly at leading-edge foundries (tsmc, samsung.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.